Utilities M&A » By The Online Investor Staff, updated Fri., Apr. 19, 2:39 AM
Recent mergers and acquisitions in the Utilities M&A category.
| This Slide: #83 of 100 |
Slide #83. Illinois Power Holdings — Ameren Energy Resources
Acquirer:
Illinois Power Holdings (DYN)
Acquiree:
Ameren Energy Resources (AEE)
Details:
Today, Dynegy (NYSE:DYN) subsidiary, Illinois Power Holdings (IPH) completed its acquisition of New Ameren Energy Resources (AER), an Ameren (NYSE:AEE) subsidiary. The transaction includes AER and its subsidiaries Ameren Energy Generating Company (Genco), New AERG (AERG), and Ameren Energy Marketing Company (AEM). Dynegy now owns more than 8,000 megawatts (MW) of generating capacity in Illinois, and nearly 14,000 MW nationally. The AEM retail and marketing businesses, doing business as Homefield Energy, and the following plants are included in the transaction: Duck Creek, Coffeen, E.D. Edwards, Newton, and Joppa.
Dyne Therapeutics is a muscle disease company focused on developing therapeutics for people living with genetically driven diseases. Co. is developing the following product candidates: DYNE-101, to address the genetic basis of myotonic dystrophy type 1 by targeting the toxic nuclear DMPK RNA that causes the disease; DYNE-251 for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44; and DYNE-301 to address the genetic basis of facioscapulohumeral dystrophy by reducing DUX4 expression in muscle tissue.
DYN SEC Filing Email Alerts Service
Preferred: DYN.PRA
Open the DYN Page at The Online Investor » Dyne Therapeutics is a muscle disease company focused on developing therapeutics for people living with genetically driven diseases. Co. is developing the following product candidates: DYNE-101, to address the genetic basis of myotonic dystrophy type 1 by targeting the toxic nuclear DMPK RNA that causes the disease; DYNE-251 for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44; and DYNE-301 to address the genetic basis of facioscapulohumeral dystrophy by reducing DUX4 expression in muscle tissue.
DYN SEC Filing Email Alerts Service
Preferred: DYN.PRA
Open the AEE Page at The Online Investor »
|
||||||||||||||||||||||||
|
|||||||||||||||||||||
 Free Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
